A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants

This study will assess the safety and tolerability of a single dose of 13-valent Pneumococcal Conjugate Vaccine for approximately 1 month after vaccination sequentially in healthy Chinese adults aged 18 through 55 years, followed by children aged 3 through 5 years, and then infants aged approximately 2 months.

Inclusion Criteria:

1. Age at the time of enrollment is:

   • 18 through 55 years (before the fifty sixth birthday) for Group 1.
   • 3 through 5 years (before the sixth birthday) for Group 2.
   • 42 to 98 days for Group 3.

2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria:

• Previous vaccination with licensed or investigational pneumococcal vaccine.
• Previous anaphylactic reaction to any vaccine or vaccine-related component.
• Contraindication to vaccination with pneumococcal vaccine.